• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    8/7/23 1:30:56 PM ET
    $ACGN
    $BIMI
    $ENVB
    $INFI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $ACGN alert in real time by email

    Gainers

    • Vistagen Therapeutics (NASDAQ:VTGN) shares rose 871.4% to $16.32 during Monday's regular session. Trading volume for this security as of 13:30 EST is 40.9 million, which is 18764.9% of its average full-day volume over the last 100 days. The company's market cap stands at $130.3 million.
    • Nektar Therapeutics (NASDAQ:NKTR) shares increased by 89.89% to $1.01. The current volume of 138.1 million shares is 4109.5% of Nektar Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $191.3 million.
    • Tabula Rasa HealthCare (NASDAQ:TRHC) stock increased by 30.84% to $10.24. Trading volume for Tabula Rasa HealthCare's stock is 3.8 million as of 13:30 EST. This is 2656.4% of its average full-day volume over the last 100 days. The company's market cap stands at $275.0 million. As per the news, the Q2 earnings report came out today.
    • Poseida Therapeutics (NASDAQ:PSTX) shares increased by 24.84% to $2.04. The current volume of 9.9 million shares is 1147.1% of Poseida Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $176.5 million.
    • Enveric Biosciences (NASDAQ:ENVB) shares rose 24.75% to $3.12. Trading volume for Enveric Biosciences's stock is 1.9 million as of 13:30 EST. This is 54.6% of its average full-day volume over the last 100 days. The company's market cap stands at $6.4 million.
    • Palatin Techs (AMEX:PTN) stock rose 19.25% to $2.35. The current volume of 348.8K shares is 653.2% of Palatin Techs's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $27.0 million.

    Losers

    • Sage Therapeutics (NASDAQ:SAGE) shares decreased by 52.3% to $17.23 during Monday's regular session. The current volume of 14.3 million shares is 1693.3% of Sage Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $1.0 billion. As per the news, the Q2 earnings report came out today.
    • Tivic Health Systems (NASDAQ:TIVC) shares decreased by 38.92% to $0.04. As of 13:30 EST, Tivic Health Systems's stock is trading at a volume of 44.9 million, which is 281.0% of its average full-day volume over the last 100 days. The company's market cap stands at $4.9 million.
    • Aceragen (NASDAQ:ACGN) stock fell 32.97% to $0.5. Aceragen's stock is trading at a volume of 245.2K shares as of 13:30 EST. This is 297.9% of its average full-day volume over the last 100 days. The company's market cap stands at $4.2 million.
    • Quantum-Si (NASDAQ:QSI) shares fell 31.72% to $2.31. As of 13:30 EST, Quantum-Si's stock is trading at a volume of 9.0 million, which is 576.4% of its average full-day volume over the last 100 days. The company's market cap stands at $327.5 million. As per the press release, Q2 earnings came out today.
    • Infinity Pharmaceuticals (NASDAQ:INFI) stock declined by 28.26% to $0.09. The current volume of 3.7 million shares is 429.1% of Infinity Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $7.7 million.
    • BIMI Intl Medical (NASDAQ:BIMI) shares decreased by 19.28% to $2.03. BIMI Intl Medical's stock is trading at a volume of 138.6K shares as of 13:30 EST. This is 89.1% of its average full-day volume over the last 100 days. The company's market cap stands at $8.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $BIMI
    $ENVB
    $INFI

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    Palatin Technologies Inc.
    $PTN
    12/12/2025$60.00Buy
    Laidlaw
    Palatin Technologies Inc.
    $PTN
    12/3/2025$50.00Buy
    Alliance Global Partners
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    More analyst ratings

    $ACGN
    $BIMI
    $ENVB
    $INFI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, March 6, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on February 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 4,300 shares of its common stock to three newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of

    3/6/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results

    Releases List Price of Proteus™ Platform Reiterates Proteus Development Program On Track for Year End 2026 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. Press Release Highlights Reported fourth quarter revenue of $451,000 Reported on track development of the Proteus platform and related R&D programs to expand proteome coverage and enable broad PTM analysis capabilities Announced list price for Proteus of $425,000 Announced 2026 Financial Guidance

    3/3/26 4:05:00 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Vistagen to Participate in Upcoming Investor Conferences

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the following upcoming March investor conferences: Leerink Healthcare Conference Date: March 9-11, 2026 Format: One-on-one meetings Location: Miami, FL Stifel 2026 Virtual CNS Forum Date: March 17, 2026 Format: Fireside chat with President and CEO Shawn Singh and one-on-one meetings Time: 9:00 AM EDT Location: Virtual The Stifel CNS presentation will be accessible via a live webcast on the "Events" page in the Inves

    3/3/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $BIMI
    $ENVB
    $INFI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $BIMI
    $ENVB
    $INFI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dowdy Paula bought $104,450 worth of shares (109,890 units at $0.95), increasing direct ownership by 69% to 269,107 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:13 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Kummeth Charles R. bought $459,800 worth of shares (500,000 units at $0.92), increasing direct ownership by 141% to 855,000 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:59 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    5/12/25 9:30:59 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $BIMI
    $ENVB
    $INFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $BIMI
    $ENVB
    $INFI
    SEC Filings

    View All

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    3/11/26 7:02:20 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Nektar Therapeutics

    SCHEDULE 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/6/26 10:05:20 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/4/26 8:30:42 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ACGN
    $BIMI
    $ENVB
    $INFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dowdy Paula bought $104,450 worth of shares (109,890 units at $0.95), increasing direct ownership by 69% to 269,107 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:13 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Kummeth Charles R. bought $459,800 worth of shares (500,000 units at $0.92), increasing direct ownership by 141% to 855,000 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:59 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Jafri Amir

    4 - Quantum-Si Inc (0001816431) (Issuer)

    2/26/26 4:05:19 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $ACGN
    $BIMI
    $ENVB
    $INFI
    Financials

    Live finance-specific insights

    View All

    Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results

    Releases List Price of Proteus™ Platform Reiterates Proteus Development Program On Track for Year End 2026 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. Press Release Highlights Reported fourth quarter revenue of $451,000 Reported on track development of the Proteus platform and related R&D programs to expand proteome coverage and enable broad PTM analysis capabilities Announced list price for Proteus of $425,000 Announced 2026 Financial Guidance

    3/3/26 4:05:00 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $BIMI
    $ENVB
    $INFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $BIMI
    $ENVB
    $INFI
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Vistagen Appoints Paul Edick to its Board of Directors

    Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,

    10/29/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care